#45 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
If endocannabinoid-targeted pharmaceuticals like these gain FDA approval, patients dealing with cancer-related weight loss and chemotherapy nerve pain could eventually have insurance-covered, standardized treatment options that work through the same system cannabis does.
Artelo Biosciences is advancing pharmaceutical candidates that target the endocannabinoid system, including ART27.13 for cancer-related anorexia and ART26.12 for chemotherapy-induced peripheral neuropathy. These drug development programs represent a growing trend of biotech companies working to create FDA-approvable medications that modulate endocannabinoid pathways rather than relying solely on plant-derived cannabinoids. The clinical significance lies in the potential for standardized, receptor-targeted therapies that could offer more predictable dosing and outcomes for patients suffering from serious cancer-related symptoms.
“The endocannabinoid system has always been the mechanism, not the plant, and every biotech dollar spent proving that brings us closer to legitimizing what my patients already experience in clinic every day.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: